Local vs. Systemic Cancer Therapy: Key Differences

Two Main Treatment Paradigms

Cancer treatment is broadly categorized by scope: targeting a specific site or treating the whole body.

Local Therapy

Targets cancer confined to one area.

• Surgery: Physical removal of tumor + margin of healthy tissue.
• Radiation therapy: High-energy beams (photons, protons) damage cancer cell DNA locally.
• Ablation/embolization: Heat (RFA), cold (cryo), or blocking blood supply (TACE) for liver/lung tumors.
• Topical/Intracavitary: Creams (skin), instillations (bladder).

Best for: Early-stage, localized solid tumors. Curative intent often possible.

Systemic Therapy

Drugs circulate throughout the bloodstream to reach cancer cells anywhere.

• Chemotherapy: Cytotoxic drugs targeting rapidly dividing cells.
• Targeted therapy: Inhibits specific molecular drivers (e.g., EGFR, HER2, BCR-ABL, VEGF).
• Immunotherapy: Checkpoint inhibitors (PD-1/PD-L1, CTLA-4), CAR-T cells, bispecific antibodies.
• Hormonal therapy: Blocks hormone receptors (ER/PR, AR) in breast/prostate cancer.
• Antibody-drug conjugates: Targeted chemo delivery.

Best for: Metastatic disease, adjuvant/neoadjuvant settings, hematologic malignancies.

Combination Approaches

Most curative regimens combine modalities: e.g., surgery → adjuvant chemo ± radiation; or neoadjuvant systemic therapy → surgery.

Decision Factors

• Cancer type, stage, molecular profile
• Patient fitness, comorbidities, preferences
• Goal: curative vs. palliative
• Access to clinical trials

A multidisciplinary tumor board (surgeon, medical oncologist, radiation oncologist, pathologist, radiologist) typically designs the optimal plan.